Cogent Biosciences…announced it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bezuclastinib in Advanced Systemic Mastocytosis (AdvSM).

bezuclastinib (PLX9486) - Cogent Biosci

Jun 30, 2026